ClinicalTrials.Veeva

Menu

Clinical Guidelines for APL Treatment

P

PETHEMA Foundation

Status and phase

Unknown
Phase 4

Conditions

APL

Treatments

Drug: Atra
Drug: Idarubicin
Drug: methotrexate

Study type

Interventional

Funder types

Other

Identifiers

NCT02020161
PETHEMA LPA2012

Details and patient eligibility

About

Therapeutic guidelines for treatment of patients with de novo APL to be used by every institution that wants to follow them. All patients who are reported may be retrospectively analyzed

Enrollment

200 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Genetic diagnosis of acute promyelocytic leukemia

Exclusion criteria

  • No exclusion criteria

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

200 participants in 1 patient group

ATRA-Idarubicin
Experimental group
Treatment:
Drug: Idarubicin
Drug: methotrexate
Drug: Atra

Trial contacts and locations

1

Loading...

Central trial contact

David Martinez, Dr; Pau Montesinos, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems